PROTHENA CORPORATION PUBLIC LIMITED COMPANY Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $6.85 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-06
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-06-30 was $6.85, a 43.61% increase year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $6.19, a 37.41% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-06-30 was $4.77, a 67.28% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $9.89, a 49.46% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $9.49, a 49.22% decline from fiscal 2024.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $18.69, a 49.92% decline from fiscal 2023.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $37.32, a 59.28% increase from fiscal 2022.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $23.43, a 9.54% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.85 10-Q · filed 2026-08-06 | $6.29 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $6.19 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $9.49 10-K · filed 2026-02-27 | |||
| 2025-09-30 | $9.49 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $4.77 10-Q · filed 2026-08-06 | $9.49 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $9.89 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $18.69 10-K · filed 2026-02-27 | |||
| 2024-09-30 | $19.21 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | $14.58 10-Q · filed 2025-08-04 | $19.21 10-Q · filed 2025-08-04 | ||
| 2024-03-31 | $19.57 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $37.32 10-K · filed 2026-02-27 | |||
| 2023-09-30 | $40.83 10-Q · filed 2024-11-12 | $37.67 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $46.10 10-Q · filed 2024-08-08 | $37.14 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $35.37 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $23.43 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $20.38 10-Q · filed 2023-11-02 | $22.53 10-Q · filed 2023-11-02 | ||
| 2022-06-30 | $20.30 10-Q · filed 2023-08-03 | $22.73 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $23.14 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $21.39 10-K · filed 2024-02-22 | |||
| 2021-09-30 | $45.53 10-Q · filed 2022-11-03 | $18.60 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $17.58 10-Q · filed 2022-08-08 | $15.93 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $15.09 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $8.12 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $8.56 10-Q · filed 2021-11-04 | $8.22 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $7.52 10-Q · filed 2021-08-05 | $8.19 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $8.32 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | $8.55 10-K · filed 2022-02-25 | |||
| 2019-09-30 | $7.09 10-Q · filed 2020-11-04 | $8.61 10-Q · filed 2020-11-04 | ||
| 2019-06-30 | $6.58 10-Q · filed 2020-08-06 | $9.06 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $9.48 10-Q · filed 2020-05-06 | |||
| 2018-12-31 | $13.70 10-K · filed 2021-02-26 | |||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-05 | $13.82 10-Q · filed 2019-11-05 | ||
| 2018-06-30 | $11.28 10-Q · filed 2019-08-06 | $13.82 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | $20.67 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | $35.71 10-K · filed 2020-03-03 | |||
| 2017-09-30 | $38.06 10-Q · filed 2018-11-06 | $35.63 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | $35.37 10-Q · filed 2018-08-07 | $35.32 10-Q · filed 2018-08-07 | ||
| 2016-12-31 | $26.41 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |